Skip to content

13F-HR filed by Prosight Management, LP

Prosight Management, LP filed this 13F-HR for the quarter ended 2018-06-30, filed 2018-08-14, with 31 holding rows worth $136,405,000.

Accession
0001420506-18-000778
Filed
2018-08-14
Accepted by EDGAR
acceptance time not in the bulk data set
Ingested
Source
SEC quarterly data set

Original filing

13F report for Q2 2018

A holdings report, 31 entries on the cover page, a total value of $136,405,000 stated on the cover page (in dollars after the unit check, H1), rows summing to $136,405,000 with VALUE read as thousands by filing date, 13F file number 028-18450. The quarter's positions are built on this report. The resolved quarter.

The information table after summing rows of one CUSIP and put or call (H4), with the CUSIP and issuer name as filed. Values in dollars after the unit check (method).

Issuer as filedCUSIPClassAmountValueValue read asType
CIGNA CORPORATION125509109COM77,400$13,154,000thousands by filing date
MACROGENICS INC556099109COM618,515$12,772,000thousands by filing date
ALLERGAN PLCG0177J108SHS71,700$11,954,000thousands by filing date
TELIGENT INC NEW87960W104COM3,325,000$11,505,000thousands by filing date
PIERIS PHARMACEUTICALS INC720795103COM1,360,000$6,895,000thousands by filing date
ATHENAHEALTH INC04685W103COMMON STOCK41,193$6,555,000thousands by filing date
ARENA PHARMACEUTICALS INC040047607COM NEW139,528$6,083,000thousands by filing date
CIDARA THERAPEUTICS INC COM NEW171757107Stock1,158,700$6,025,000thousands by filing date
IOVANCE BIOTHERAPEUTICS INC462260100COM439,900$5,631,000thousands by filing date
BIOMARIN PHARMACEUTICAL INC09061G101COM57,900$5,454,000thousands by filing date
SHIRE PLC82481R106COMMON STOCK-FO32,000$5,402,000thousands by filing date
EIGER BIOPHARMACEUTICALS INC28249U105COM438,422$5,349,000thousands by filing date
SIERRA ONCOLOGY INC82640U107COM1,806,562$5,347,000thousands by filing date
KURA ONCOLOGY INC COM50127T109Stock287,887$5,240,000thousands by filing date
INTEC PHARMA LTD JERUSALEMM53644106SHS1,125,153$4,951,000thousands by filing date
ACHAOGEN INC004449104COM375,000$3,248,000thousands by filing date
MYLAN NVN59465109SHS EURO80,800$2,920,000thousands by filing date
REATA PHARMACEUTICALS INC75615P103CL A83,094$2,906,000thousands by filing date
ASSEMBLY BIOSCIENCES INC045396108COM65,301$2,560,000thousands by filing date
SABRA HEALTH CARE REIT INC COM78573L106REIT98,906$2,149,000thousands by filing date
ESPERION THERAPEUTICS INC NEW COM29664W105Stock48,800$1,912,000thousands by filing date
PARATEK PHARMACEUTICALS INC699374302Equity144,752$1,476,000thousands by filing date
NABRIVA THERAPEUTICS PLCG63637105SHS421,414$1,467,000thousands by filing date
CENTENE CORP DEL COM15135B101Stock10,875$1,340,000thousands by filing date
AQUINOX PHARMACEUTICALS INC03842B101COM400,900$1,062,000thousands by filing date
KEZAR LIFE SCIENCES INC49372L100COM41,691$721,000thousands by filing date
NOVELION THERAPEUTICS INC67001K202COM NEW194,663$716,000thousands by filing date
CIVITAS SOLUTIONS INC17887R102COM34,649$568,000thousands by filing date
CELLECTIS ADS15117K103COM19,388$548,000thousands by filing date
AVEO PHARMACEUTICALS INC053588109COM149,073$337,000thousands by filing date
AVEO PHARMACEUTICALS INC053588909COM70,100$158,000thousands by filing datecall

Amendment chain

FilingRoleFiledAcceptedIngested
13F-HR 0001420506-18-000778this filing2018-08-14acceptance time not in the bulk data set